FierceBiotech names Fulcrum Therapeutics as one of its “Fierce 15” Biotech Companies of 2016
September 19, 2016
Cambridge, MA – September 19, 2016 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control, today announced that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Fulcrum was launched in July 2016 with a focus on discovering and developing small molecules based on some of the biggest biologic breakthroughs of the last decade. The unraveling of gene regulation at a molecular level enables the modulation of on/off control mechanisms that regulate genes. The company integrates these advances with a wide range of biological disciplines, including stem cell biology, genetics, and computational biology, to discover and develop new medicines that restore health.
“We are honored to be chosen as a Fierce 15 company, reflecting the uniqueness of our approach targeting the mechanisms of gene regulation to develop novel therapies for a wide range of serious diseases,” said Robert J. Gould, Ph.D., Fulcrum’s President and Chief Executive Officer. “We are building Fulcrum Therapeutics with a clear scientific focus and strong sense of purpose as we seek to develop new medicines to deliver a new future for patients who currently have no other therapeutic options.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual Fierce 15 selection. The 2015 list of “Fierce 15” companies can be found online at www.fiercebiotech.com/special-report/fiercebiotech-s-2015-fierce-15.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more.
More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information please visit www.fulcrumtx.com
Ten Bridge Communications